Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm Taiwan's revenue for the
three
months ended in Mar. 2026 was NT$660 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$3,137 Mil.
Scinopharm Taiwan's Revenue per Share for the
three
months ended in Mar. 2026 was NT$0.83.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$3.91.
Warning Sign:
Scinopharm Taiwan Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Scinopharm Taiwan was 0.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Scinopharm Taiwan's highest 3-Year average Revenue per Share Growth Rate was 7.20% per year. The lowest was -10.40% per year. And the median was -2.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Scinopharm Taiwan Revenue Related Terms
Scinopharm Taiwan Revenue Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Revenue distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,137 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Revenue of NT$3,137 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Revenue too high?
Scinopharm Taiwan's current Revenue is NT$3,137 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Revenue compare to ZTS?
Scinopharm Taiwan's Revenue of NT$3,137 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Revenue is NT$3,137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.11, compared to a current price of NT$19.00 — trading 24.3% below its estimated fair value. The current Revenue is NT$3,137 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Revenue is NT$3,137 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.00 is trading 24.3% below its estimated GF Value™ of NT$25.11.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Revenue: NT$3,137 Mil
GF Value™: NT$25.11 vs. price of NT$19.00 (24.3% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
